Ashchem Pharmacy acquired by Juno Health

Investor-backed pharmacy group Juno Health acquired Ashchem Chemists, one of the largest independent retail pharmacy chains in North East England, in an October 2017 sell-side transaction led by James Pugh — now Co-founder and Partner at CapEQ.

Overview of Ashchem

Founded by Ash Aggarwal in 1981, Ashchem Chemists grew from a single pharmacy to one of the largest independent retail pharmacy groups in the North East of England.

By the point of sale the chain operated 15 branches across Newcastle, Gateshead, Sunderland, and Durham, employing approximately 120 pharmacy and patient-facing staff.

The business had been built over 35 years on a model that placed clinical patient care, well-trained pharmacy teams, and long-term community relationships at the centre of every branch.

start your business sale journey today

Deal at a glance

Target	Ashchem Chemists (Ashchem Pharmacy)
Acquirer	Juno Health, Milton Keynes, United Kingdom
Completion date	18 October 2017
Deal value	Undisclosed
Deal structure	Share sale — undisclosed terms
Sell-side M&A advisor	James Pugh Now CapEQ
Legal advisor to Ashchem	Mincoffs Solicitors (John Nicholson, Corporate Partner)
Sector	Community pharmacy — dispensing chemists in specialised stores (UK SIC 47.73)
Target HQ	North East England (Newcastle, Gateshead, Sunderland, Durham)
Founded	1981 by Ash Aggarwal
Branches at completion	15 pharmacies
Staff at completion	Approximately 120
Customer base	NHS dispensing patients across Tyne and Wear, County Durham, and the wider North East
Post-acquisition status	Integrated into Juno Health; Juno Health later received investment from Bregal Freshstream (2018)

Ashchem Chemists pharmacy branch in North East England — 15-branch chain sold to Juno Health

Strategic acquisition by Juno Health

Juno Health, headquartered in Milton Keynes, was led by CEO Mark Peatey and a senior team drawn from the largest UK pharmacy and multi-site retail operators — including former leadership from Lloydspharmacy, Sainsbury's pharmacy estate, and IDH. Juno Health had been established to consolidate independent UK pharmacy groups and deliver a modernised, patient-centred, locally trusted brand.

The Ashchem acquisition was Juno Health's first transaction since inception, and gave the group an immediate regional footprint of 15 branches and an experienced operating team.

In 2018, the year after this transaction, Juno Health secured investment from Bregal Freshstream to support further scale-up.

How the deal came together

The UK pharmacy M&A backdrop in 2017

UK community pharmacy entered a period of structural change through 2016 and 2017, driven by NHS funding pressure, a tightening regulatory environment, and the emergence of well-capitalised consolidators seeking to build regional and national chains.

For founder-led independent groups with strong patient relationships and stable dispensing volumes, the window for a sale to a strategic buyer who would retain branches and staff was narrowing as the larger consolidators moved quickly.

Ashchem had reached the scale at which it was a natural target for exactly that kind of acquirer — and Ash Aggarwal had reached the stage in his ownership journey where a properly run sale process, on his terms, was the right next step.

Finding the right acquirer

The task was to identify acquirers for whom Ashchem's branch network, patient base, and trained pharmacy workforce represented genuine strategic value — rather than a cost-reduction exercise.

Juno Health's stated thesis was to reinvent the family pharmacy by investing in its workforce and patient services, and its leadership team brought operational depth from the largest UK pharmacy groups.

That combination of strategic intent and operational capability identified Juno Health early as a natural home for the business — one that would honour the 35 years of work behind it.

Running a process that protected value

The process was structured to establish a defensible valuation and to protect Ashchem's staff and patient relationships throughout.

James Pugh managed buyer communications, coordinated the legal and financial workstreams, and acted as the buffer between the live business and the transaction — allowing Ash Aggarwal to continue running the branches normally during the engagement.

Staff continued to be supported, patient services continued without interruption, and the operational rhythm of the group remained intact.

That continuity is what gave acquirers confidence in the underlying earnings and supported the quality of the offer ultimately received.

Completing on the right terms

The transaction completed on 18 October 2017 on undisclosed terms. The structure preserved continuity for Ashchem's patients across all 15 branches and brought approximately 120 staff into the Juno Health network.

Ash Aggarwal's clearly stated priority — that the team he had built and the patient care standards he had set should be retained — was reflected directly in the integration plan.

Juno Health later secured Bregal Freshstream investment in 2018 and subsequently developed into a national pharmacy platform.

Enhancing the Juno Health pharmacy network

The Ashchem acquisition gave Juno Health an immediate regional footprint in the North East — a market with a well-established independent pharmacy tradition and a patient base that valued continuity.

The combined operating team, drawing on Ashchem's branch knowledge and Juno Health's leadership experience from the largest UK pharmacy groups, set the platform for the consolidation strategy Juno Health subsequently pursued.

James Pugh, sell-side M&A advisor to Ashchem Chemists

Droitwich Pharmacy acquired by MSA Global

M&A advisory support

Ashchem founder Ash Aggarwal received sell-side corporate finance advisory from James Pugh — now Co-founder and Partner at CapEQ — and legal advice from Newcastle law firm Mincoffs Solicitors, led by corporate partner John Nicholson. The price and terms of the deal remain undisclosed.

"It was a privilege to advise Ash on the sale of a business he had built over 35 years. The job was to find a buyer who would honour what he had built — for his staff and for his patients — and to run the process in a way that protected the business throughout. Juno Health's leadership team brought exactly the operational depth and the patient-care intent that this acquisition needed."

James Pugh, now Co-founder and Partner, CapEQ

About Ashchem Chemists

Founded by Ash Aggarwal in 1981 and headquartered in the North East of England, Ashchem Chemists grew over 35 years from a single pharmacy into one of the largest independent retail pharmacy chains in the region.

At the point of sale the group operated 15 branches across Newcastle, Gateshead, Sunderland, and Durham. The business was built around clinical patient care, well-trained pharmacy teams, and long-term community relationships, and at completion employed approximately 120 staff.

About Juno Health

Founded and headquartered in Milton Keynes, Juno Health was established to consolidate and modernise independent UK community pharmacy.

Its founding leadership team brought senior operating experience from Lloydspharmacy, Sainsbury's pharmacy estate, and IDH (Europe's largest dental care provider).

The Ashchem acquisition was Juno Health's first transaction.

In 2018 the group secured investment from Bregal Freshstream to support further scale-up and continued to acquire and integrate community pharmacy businesses in subsequent years.

Client feedback

:I had the good fortune to work with James when I sold my chain of pharmacies, one of the top 50 in the country, in 2017.

Unlike many advisors and agents I found James to be a really refreshing change; he spent a long time listening and understanding me and we developed an excellent rapport. Its not often that your professional advisors also become friends, but our relationship is testament to the mutual respect we developed for each other.

It was clear that James' knowledge, experience and work ethic were second to none. He was always available 24/7 on the phone to support me or was quite happy to travel 6 hours to come and see me regularly. We formed an unbeatable team and we worked really well together- he was as happy to listen to me as I was to listen to him, and his input at times was crucial. His knowledge of private equity and how they work was fundamental to completing the transaction.

Honest and trustworthy with a great understanding of me and my business it was a pleasure to work with James and the outcome was superb. I thoroughly recommend anyone looking for corporate finance advice should speak with James.

Ash Aggarwal, founder

Ashchem (UK)

explore more founder exits

What acquirers value in UK community pharmacy

Strategic acquirers in UK community pharmacy focus on a consistent set of value drivers: NHS dispensing volume and item-count stability, branch geographic density and catchment quality, the pharmacist workforce and locum dependency profile, services revenue beyond dispensing (such as flu vaccinations, NHS New Medicine Service participation, and private clinical services), and the condition and lease terms of branch premises. A founder-led, owner-operated group with a long-standing patient base, low staff turnover, and a clear branch-level operating discipline is consistently viewed as a lower-risk acquisition and commands a stronger valuation in a competitive sell-side M&A process.

UK community pharmacy is conventionally valued on a multiple of adjusted EBITDA, with multiples shaped by item-count trend, services-revenue mix, branch quality, and the buyer universe active at the time of the process. In UK mid-market M&A — where transaction values typically sit in the £5m–£100m range — well-run multi-branch groups with stable dispensing volumes and a credible operating team can attract meaningful competitive interest from consolidator buyers backed by private equity. A competitive sell-side process run by an experienced UK M&A advisor with sector context is the most reliable way to establish a defensible valuation and to prevent the first inbound approach from anchoring the negotiation.

UK community pharmacy remains one of the most consistently transactable healthcare sub-sectors. Independent multi-branch groups are attractive to investor-backed consolidators for a combination of reasons: a regulated, contracted NHS revenue stream that is highly recurring; a defined service expansion path through NHS clinical services and private healthcare delivery; the ability to apply central procurement, technology, and operating scale to acquired branches; and a fragmented market that supports a buy-and-build strategy. The Juno Health acquisition of Ashchem in 2017 is a clear illustration — Juno Health used the Ashchem branch network as a platform for further scale and subsequently received institutional investment from Bregal Freshstream.

The outcome for pharmacy staff and patients depends on the acquirer's integration plan and the strength of the terms negotiated. Consolidator acquirers typically retain branch teams, pharmacist roles, and patient relationships, because continuity of dispensing and patient trust is central to the recurring NHS revenue they have acquired. In the Ashchem transaction, the 15 branches and approximately 120 staff were brought into the Juno Health network with continuity of patient services as a stated integration objective. Working with founders to identify acquirers whose operating intent and values align with the legacy they want to protect — and to write team and patient protections into the deal where possible — is central to how a values-led sell-side process should be run.

Founder challenges — selling a UK community pharmacy chain

Exit timing for an independent pharmacy owner is shaped by personal, business, and market factors in combination. On the personal side: clarity about retirement intent, family succession options, and energy for the next two to three years of running the business. On the business side: a stable item-count trend, demonstrable services revenue, manageable locum dependency, and a branch portfolio in good repair. On the market side: the activity level of consolidator acquirers, the funding environment for institutional buyers, and any NHS contractual changes on the horizon. Owners who plan their exit two to three years in advance — and prepare the business accordingly — consistently achieve stronger outcomes than those who go to market reactively.

Running the business while in process is one of the most common concerns owner-operators raise — and it is a valid one. A structured sell-side process places real demands on the owner's time and attention precisely when normal operational momentum matters most. The right UK M&A advisor manages the process around the owner's capacity: handling buyer communications, coordinating legal and financial advisors, and acting as a buffer between the branches and the transaction. In the Ashchem transaction Ash Aggarwal continued to run his 15-branch group throughout the process — patient services continued without interruption and the operating rhythm of the business was preserved.

A typical structured sell-side M&A process for a multi-branch UK community pharmacy group takes between six and twelve months from formal advisor appointment to legal completion. Timelines are influenced by the readiness of financial and operational documentation, the number of credible acquirers engaged, the pace of buyer due diligence, and any regulatory or NHS contractual matters that need to be addressed. Where an owner has pre-existing relationships with potential consolidators — or where an acquirer approaches inbound — the timeline can compress, but this should not be confused with a reduction in process rigour. Agreeing a realistic timetable at the outset, with milestones that are communicated clearly and met consistently, is fundamental to a confident outcome.

Choosing the right sell-side M&A advisor for a UK pharmacy or healthcare business comes down to three things: sector-specific valuation fluency, a demonstrable track record of completed transactions in healthcare and regulated services, and independence from conflicts of interest. A generalist advisor may be able to run a process, but an advisor who understands NHS contractual mechanics, the pharmacy consolidator buyer universe, and the operational diligence that healthcare acquirers will run is what produces a materially better outcome. CapEQ is a Certified B Corporation — independently certified to prioritise client outcomes over deal income — and has supported founders across community healthcare, pharmacy, and clinical services with both trade and investor-backed buyers.

We'd love to hear your story

Let's chat about your future plans. We can help you get clear on where your business journey is going.

book a chat with james